Skip to main content
Top
Published in: Breast Cancer Research and Treatment 2/2004

01-03-2004

Preclinical Therapy of Breast Cancer with a Radioiodinated Humanized Anti-EGP-1 Monoclonal Antibody: Advantage of a Residualizing Iodine Radiolabel

Authors: Serengulam V. Govindan, Rhona Stein, Zhengxing Qu, Susan Chen, Philip Andrews, Hong Ma, Hans J. Hansen, Gary L. Griffiths, Ivan D. Horak, David M. Goldenberg

Published in: Breast Cancer Research and Treatment | Issue 2/2004

Login to get access
Metadata
Title
Preclinical Therapy of Breast Cancer with a Radioiodinated Humanized Anti-EGP-1 Monoclonal Antibody: Advantage of a Residualizing Iodine Radiolabel
Authors
Serengulam V. Govindan
Rhona Stein
Zhengxing Qu
Susan Chen
Philip Andrews
Hong Ma
Hans J. Hansen
Gary L. Griffiths
Ivan D. Horak
David M. Goldenberg
Publication date
01-03-2004
Publisher
Kluwer Academic Publishers
Published in
Breast Cancer Research and Treatment / Issue 2/2004
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI
https://doi.org/10.1023/B:BREA.0000018417.02580.ef

Other articles of this Issue 2/2004

Breast Cancer Research and Treatment 2/2004 Go to the issue

Instructions for Authors

Instructions for Authors

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine